MAIA Biotechnology, Inc. (MAIA)
XASE:MAIA
Top Page
No summary available
Positive Factors
Clinical Trial Success
The promising results from the Phase 2 THIO-101 trial indicate a potential breakthrough in cancer treatment, enhancing MAIA's regulatory strategy and expediting FDA approval, which could significantly boost the company's market position and revenue potential.
Negative Factors
Lack of Revenue
The absence of revenue generation reflects the company's early-stage status and reliance on external funding, posing a risk to financial sustainability and limiting its ability to self-fund R&D and operational activities in the long term.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical Trial Success
The promising results from the Phase 2 THIO-101 trial indicate a potential breakthrough in cancer treatment, enhancing MAIA's regulatory strategy and expediting FDA approval, which could significantly boost the company's market position and revenue potential.
Read all positive factors
MAIA Biotechnology, Inc. (MAIA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$82.51M
Dividend YieldN/A
Average Volume (3M)570.23K
Price to Earnings (P/E)―
Beta (1Y)1.43
Revenue GrowthN/A
EPS Growth44.50%
CountryUS
Employees13
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.11
Shares Outstanding60,671,490
10 Day Avg. Volume650,834
30 Day Avg. Volume570,232
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)20.68
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap-104.29
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda595.46
Forecast
1Y Price Target
$14.00Price Target Upside704.60% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.69
Revenue Forecast (FY)N/A
MAIA Biotechnology, Inc. Business Overview & Revenue Model
Company Description
MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer, primarily non-small cell lung cancer. Its lead asset, THIO, is an investigational dual me...
How the Company Makes Money
MAIA Biotechnology, Inc. makes money primarily through the development and commercialization of oncology therapies. The company's revenue model includes securing funding through partnerships, licensing agreements, and collaborations with other pha...
MAIA Biotechnology, Inc. Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -24.27M | -23.25M | -19.77M | -15.76M | -11.75M |
| Net Income | -22.40M | -23.25M | -19.77M | -15.77M | -12.50M |
Balance Sheet | |||||
| Total Assets | 9.70M | 10.16M | 7.57M | 12.02M | 11.33M |
| Cash, Cash Equivalents and Short-Term Investments | 8.66B | 9.60M | 7.15M | 10.95M | 10.57M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 7.33M | 6.52M | 7.09M | 3.51M | 2.15M |
| Stockholders Equity | 2.38M | 3.63M | 477.51K | 8.51M | 9.18M |
Cash Flow | |||||
| Free Cash Flow | -18.84B | -15.70M | -13.07M | -12.10M | -4.12M |
| Operating Cash Flow | -18.84B | -15.70M | -13.07M | -12.10M | -4.12M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 17.91B | 18.18M | 9.27M | 12.48M | 14.03M |
MAIA Biotechnology, Inc. Technical Analysis
Neutral
1.74
Price Trends
1.68
Negative
1.61
Negative
1.58
Negative
Market Momentum
-0.10
Negative
45.25
Neutral
65.43
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MAIA, the sentiment is Neutral. The current price of 1.74 is above the 20-day moving average (MA) of 1.37, above the 50-day MA of 1.68, and above the 200-day MA of 1.58, indicating a neutral trend. The MACD of -0.10 indicates Negative momentum. The RSI at 45.25 is Neutral, neither overbought nor oversold. The STOCH value of 65.43 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for MAIA.
MAIA Biotechnology, Inc. Risk Analysis
MAIA Biotechnology, Inc. disclosed 72 risk factors in its most recent earnings report. MAIA Biotechnology, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
MAIA Biotechnology, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | $82.51M | -3.39 | -3.76% | ― | ― | 44.50% | |
52 Neutral | $60.85M | -0.66 | -115.64% | ― | ― | 46.20% | |
49 Neutral | $48.92M | -21.38 | -311.80% | ― | 588.40% | 61.76% | |
46 Neutral | $38.20M | -2.04 | -83.24% | ― | -100.00% | 55.10% | |
46 Neutral | $50.52M | -1.28 | -105.17% | ― | ― | ― |
* Healthcare Sector Average
MAIA
MAIA Biotechnology, Inc.
1.37
-0.17
-11.04%
VERU
Veru
2.42
-2.83
-53.90%
OKUR
OnKure Therapeutics
4.61
1.68
57.17%
XLO
Xilio Therapeutics
8.59
-2.02
-19.04%
RADX
Radiopharm Theranostics Limited Sponsored ADR
4.60
0.40
9.52%
MAIA Biotechnology, Inc. Corporate Events
Business Operations and StrategyPrivate Placements and Financing
MAIA Biotechnology Announces $2.25M Private Placement Deal
Positive
Dec 17, 2025
On December 16, 2025, MAIA Biotechnology, Inc. entered into a Securities Purchase Agreement with accredited investors and directors for a private placement of common stock and warrants worth approximately $2.25 million. The director participation ...
Business Operations and StrategyProduct-Related Announcements
MAIA Biotechnology Announces Significant Insider Buying
Positive
Dec 11, 2025
On December 11, 2025, MAIA Biotechnology, Inc. announced significant insider buying by its leadership, including CEO Dr. Vlad Vitoc, who acquired 182,445 shares in late November 2025. This insider activity, alongside encouraging clinical results f...
Business Operations and StrategyProduct-Related Announcements
MAIA Biotechnology Advances NSCLC Treatment with Ateganosine
Positive
Dec 10, 2025
On December 10, 2025, MAIA Biotechnology announced a significant advancement in the treatment of advanced non-small cell lung cancer (NSCLC) with their telomere-targeting agent, ateganosine. This new therapeutic class aims to address the unmet med...
Business Operations and StrategyProduct-Related Announcements
MAIA Biotechnology Highlights Ateganosine Progress at SITC 2025
Positive
Nov 21, 2025
On November 21, 2025, MAIA Biotechnology announced the ongoing progress of its ateganosine clinical program at the SITC 2025 conference. The company highlighted the enrollment of 12 patients in the Phase 2 THIO-101 trial and the commencement of pa...
Business Operations and StrategyProduct-Related Announcements
MAIA Biotechnology Expands Phase 2 Study in Romania
Positive
Nov 20, 2025
On November 20, 2025, MAIA Biotechnology announced that its CEO, Vlad Vitoc, presented the efficacy of their telomere-targeting agent, ateganosine, at the Smart Diaspora 2025 conference in Romania. The company has begun enrolling patients in Roman...
Business Operations and StrategyProduct-Related Announcements
MAIA Biotechnology Presents Posters at Cancer Conference
Positive
Nov 7, 2025
MAIA Biotechnology, Inc. announced the presentation of two posters at the Society for Immunotherapy of Cancer conference in November 2025. The posters detail ongoing Phase 2 and Phase 3 studies of Ateganosine (THIO) in combination with immune chec...
Business Operations and StrategyProduct-Related Announcements
MAIA Biotechnology Presents at 2025 Cancer Conference
Positive
Oct 27, 2025
On October 27, 2025, MAIA Biotechnology announced its participation in the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, where they presented a trial in progress poster for their THIO-101 Phase 2 clinic...
Business Operations and Strategy
MAIA Biotechnology Showcases Promising Cancer Trial Results
Positive
Oct 23, 2025
On October 23, 2025, MAIA Biotechnology announced the presentation of two e-posters at the European Society for Medical Oncology Congress 2025 in Berlin, detailing ongoing Phase 2 and Phase 3 clinical trials of ateganosine in non-small cell lung c...
Private Placements and Financing
MAIA Biotechnology Announces Private Placement Agreement
Neutral
Oct 14, 2025
On October 13, 2025, MAIA Biotechnology, Inc. announced a Securities Purchase Agreement with accredited investors for a private placement of 603,769 shares of common stock and warrants, raising approximately $736,600. The proceeds will be used to ...
Business Operations and Strategy
MAIA Biotechnology Adopts New Digital Asset Strategy
Positive
Oct 7, 2025
On October 7, 2025, MAIA Biotechnology, Inc. announced a new digital asset treasury strategy, authorizing up to 90% of its liquid assets to be held in cryptocurrencies such as Bitcoin, Ethereum, and USD Coin. This move aims to diversify MAIA’...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―